Novartis Claims First H1N1 Swine Flu Vaccine, "Ready by Autumn"

All major drugmakers received the H1N1 wild-type strain from the WHO two weeks ago to enable them to develop the vaccine, but Novartis is the first one to have said it will have the vaccines ready but this fall. Novartis said its research showed that it was quicker to make the vaccine through cell-based production, rather than traditional egg-based manufacturing.

The WHO has estimated vaccine makers could produce up to 4.9 billion pandemic flu shots a year in a best-case scenario, leaving some of the world's 6.5 billion population unprotected, particularly if more than one injection was needed to gain immunity.

She was detected at the airport in the northern Moroccan city of Fez because she showed symptoms of high fever and is being treated in a local hospital.